The company have substantially advanced the development of a novel therapy for amyloid heart disease, leveraging Attruby. Early trial information reveals promising improvements for patients suffering from this serious condition. This focus highlights BridgeBio's dedication to treating unmet medical needs in a cardiology arena. Attruby: BridgeBio's